Lung Cancer Clinical Trials


Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Conditions:   EGFR Exon 20 Insertion Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified June 2017

Learn More

The Lung Screening, Tobacco and Health Project

Conditions:   Smoking, Tobacco;   Tobacco-Related Carcinoma;   Tobacco Use;   Lung Cancer Screening
Interventions:   Behavioral: Intensive Telephone Counseling with nicotine replacement;   Behavioral: Usual Care
Sponsors:   Georgetown University;   Hackensack University Medical Center;   Baptist Health South Florida;   Hartford HealthCare;   Lahey Hospital and Medical Center;   Truth Initiative;   University of Michigan;   National Cancer Institute (NCI)
Recruiting - verified June 2017

Learn More

A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Condition:   Neoplasms
Interventions:   Drug: Alectinib;   Drug: Crizotinib
Sponsor:   Hoffmann-La Roche
Not yet recruiting - verified June 2017

Learn More

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Conditions:   EGFR Exon 20 Insertion Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Osimertinib
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting - verified June 2017

Learn More

The Lung Screening, Tobacco and Health Project

Conditions:   Smoking, Tobacco;   Tobacco-Related Carcinoma;   Tobacco Use;   Lung Cancer Screening
Interventions:   Behavioral: Intensive Telephone Counseling with nicotine replacement;   Behavioral: Usual Care
Sponsors:   Georgetown University;   Hackensack University Medical Center;   Baptist Health South Florida;   Hartford HealthCare;   Lahey Hospital and Medical Center;   Truth Initiative;   University of Michigan;   National Cancer Institute (NCI)
Recruiting - verified June 2017

Learn More

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

Conditions:   Cigarette Smoker;   Current Smoker;   Lung Adenocarcinoma;   Squamous Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions:   Other: Best Practice;   Procedure: Biospecimen Collection;   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Medical Chart Review;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Behavioral: Smoking Cessation Intervention
Sponsor:   Ohio State University Comprehensive Cancer Center
Not yet recruiting - verified June 2017

Learn More

Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers

Conditions:   Breast Cancer;   Head and Neck Squamous Cell Carcinoma;   Non Small Cell Lung Cancer;   Hepatocellular Cancer;   Colorectal Cancer;   Gastric Adenocarcinoma;   Melanoma;   Advanced Cancer
Intervention:   Drug: C188-9
Sponsors:   StemMed, Ltd., USA;   M.D. Anderson Cancer Center
Not yet recruiting - verified June 2017

Learn More

Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Procedure: Thoracic Surgery
Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Recruiting - verified June 2017

Learn More

A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Condition:   Neoplasms
Interventions:   Drug: Alectinib;   Drug: Crizotinib
Sponsor:   Hoffmann-La Roche
Not yet recruiting - verified June 2017

Learn More

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Condition:   Non Small Cell Lung Cancer NSCLC
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Drug: Abraxane + carboplatin;   Drug: Gemcitabine + cisplatin;   Drug: Gemcitabine + carboplatin;   Drug: Pemetrexed + carboplatin;   Drug: Pemetrexed + cisplatin
Sponsor:   AstraZeneca
Recruiting - verified June 2017

Learn More

A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for Lung Cancer Surgery

Condition:   Lung Cancer
Intervention:   Behavioral: Exercise
Sponsors:   Dartmouth-Hitchcock Medical Center;   Norris Cotton Cancer Center;   Dartmouth College
Not yet recruiting - verified June 2017

Learn More

A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer

Conditions:   Non-Small Cell Lung Cancer;   Urinary Bladder Neoplasms;   Neoplasm Metastasis
Intervention:   Drug: Combination of NKTR-214 + atezolizumab
Sponsor:   Nektar Therapeutics
Recruiting - verified June 2017

Learn More

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Afatinib;   Drug: pembrolizumab
Sponsor:   Boehringer Ingelheim
Not yet recruiting - verified June 2017

Learn More

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Conditions:   Solid Tumor, Adult;   Breast Cancer;   Non Small Cell Lung Cancer;   Prostate Cancer;   Ovarian Cancer;   Endometrial Cancer;   Head and Neck Cancer;   Cholangiocarcinoma
Intervention:   Drug: CX-2009
Sponsor:   CytomX Therapeutics
Recruiting - verified June 2017

Learn More

Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR

Conditions:   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Non-small Cell Lung Cancer
Interventions:   Radiation: Stereotactic Ablative Radiotherapy;   Drug: Nivolumab
Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Recruiting - verified June 2017

Learn More

1-15 of 130
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.